May 19, 2021
News
April 6, 2021
Artiva Biotherapeutics Appoints Michael E. Faerm as Chief Financial Officer
February 26, 2021
Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
January 28, 2021
Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies
January 5, 2021
Artiva Biotherapeutics Announces Appointment of Dr. Fred Aslan as President and CEO
December 7, 2020
Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell Lymphomas
November 5, 2020
Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies
June 26, 2020